	US 12,121,574 B2
	Malaria immunogen and methods for using same
Bryce C. Chackerian, Albuquerque, NM (US); Fidel P. Zavala, Baltimore, MD (US); David S. Peabody, Albuquerque, NM (US); Nikolai Petrovsky, Adelaide (AU); and Lucie Jelinkova, Albuquerque, NM (US)
Assigned to UNM RAINFOREST INNOVATIONS, Albuquerque, NM (US); THE JOHNS HOPKINS UNIVERSITY, Baltimore, MA (US); and VAXINE PTY LTD., Bedford Park (AU)
Filed by UNM RAINFOREST INNOVATIONS, Albuquerque, NM (US); THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD (US); and VAXINE PTY LTD., Bedford Park (AU)
Filed on Sep. 27, 2022, as Appl. No. 17/953,712.
Claims priority of provisional application 63/249,281, filed on Sep. 28, 2021.
Prior Publication US 2023/0102159 A1, Mar. 30, 2023
Int. Cl. A61K 39/002 (2006.01); A61K 39/00 (2006.01); A61K 39/015 (2006.01); A61P 33/06 (2006.01); C12N 15/63 (2006.01)

CPC A61K 39/015 (2013.01) [A61P 33/06 (2018.01); C12N 15/63 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/55561 (2013.01)]

32 Claims

1. An immunogen comprising:

an immunogenic carrier comprising a Qβ bacteriophage virus-like particle (VLP); and

an antigenic malaria circumsporozoite protein (CSP) junction region peptide comprising NANPNVDPNANPNVD (SEQ ID NO:2) linked to the immunogenic carrier.